Aliskiren
- Generic Name
- Aliskiren
- Brand Names
- Rasilez, Tekturna, Tekturna Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C30H53N3O6
- CAS Number
- 173334-57-1
- Unique Ingredient Identifier
- 502FWN4Q32
- Background
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
- Indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.
- Associated Conditions
- Hypertension
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 180
- Registration Number
- NCT00219050
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
🇪🇸Investigative Site, Madrid, Spain
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
- Conditions
- Hypertension, Diabetes Mellitus
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 839
- Registration Number
- NCT00219089
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 504
- Registration Number
- NCT00219076
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 844
- Registration Number
- NCT00219063
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 641
- Registration Number
- NCT00219193
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 250
- Registration Number
- NCT00171405
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
- Conditions
- Diabetic Nephropathy
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 496
- Registration Number
- NCT00097955
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇬🇧Investigative Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.